Status:
NOT_YET_RECRUITING
Relationship Between FGF19 Overexpression and Disease Prognosis
Lead Sponsor:
Beijing Tsinghua Chang Gung Hospital
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Brief Summary
A real-world study of FGF19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma
Detailed Description
This is a real-world, single-arm, observational study to collect information on the diagnosis and prognosis of hepatocellular carcinoma patients with previous tissue samples in routine clinical practi...
Eligibility Criteria
Inclusion
- Age ≥18 years on the day of signing the informed consent form
- Histologically or clinically confirmed diagnosis of intermediate to advanced HCC
- Adequate tissue samples of previous liver cancer
- Expected survival of more than 3 months
Exclusion
- Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes
- Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06938451
Start Date
May 1 2025
End Date
December 31 2028
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tsinghua Changgung Hospital
Beijing, China